Invega, an atypical antipsychotic medication that contains an active metabolite of the drug Risperdal, may be associated with gynecomastia, a condition that causes excessive male breast growth. Thousands of < ahref="http://bl.risperdallawsuitcenter.com/">Risperdal lawsuits involving the disorder have already been filed in courts around the country. Men and boys who experienced similar complications while using Invega may be entitled to take legal action of their own.
The nationwide law firm of Bernstein Liebhard LLP offers free legal reviews to individuals interested in pursuing an Invega lawsuit for gynecomastia. If you would like to discuss a claim with our legal team, please call today.
Invega is marketed by Johnson & Johnson’s Janssen Pharmaceuticals unit, and was approved by the U.S. Food & Drug Administration in 2006. It is currently indicated:
Invega Sustenna is an injectable version of the medication that is administered once per month.
Although Invega was approved only for the treatment of schizophrenia and schizoaffective disorder, the U.S. Department of Justice has alleged that Johnson & Johnson and Janssen marketed the drug for off-label indications and made false and misleading statements about its safety and efficacy. In November 2013, the companies agreed to pay $2.2 billion to settle those charges, as well as similar charges involving Risperdal and other medications.
A number of studies have suggested that Risperdal may cause male breast growth, a condition known as gynecomastia. According to this research, risperidone, the active ingredient in that drug, stimulates the body to produce excess amounts of prolactin, a hormone that plays a role in female breast development and lactation. High levels of this hormone are also thought to play a role in gynecomastia. Because Invega contains an active metabolite of risperidone, it has a prolactin-elevating effect similar to that seen with Risperdal.
While no Invega lawsuits involving gynecomastia have gone to trial, a number of Risperdal cases filed over the condition have been heard by juries in a mass tort litigation currently underway in Pennsylvania’s Philadelphia Court of Common Pleas. As of July 2016, five juries had found that Johnson & Johnson failed to provide patients and doctors with adequate warnings regarding the link between Risperdal and gynecomastia. Four plaintiffs have been awarded significant financial judgments, with compensatory damages ranging from $70 million to $500,000.
Invega users who may be eligible to file a similar lawsuit include those who experienced:
Victims of gynecomastia that may be related to the use of Invega could be entitled to compensation for bills associated with their medical treatments, emotional distress, pain and suffering, and more. To learn if you qualify to file an Invega lawsuit, please contact Bernstein Liebhard LLP today at .